Update on quinolone-containing rescue therapies for Helicobacter pylori infection  

作　　者：Hideki Mori Hidekazu Suzuki 

机构地区：[1]Department of Clinical and Experimental Medicine,Translational Research Center for Gastrointestinal Disorders,University of Leuven,Leuven 3000,Belgium [2]Division of Gastroenterology and Hepatology,Department of Internal Medicine,Tokai University School of Medicine,Isehara 259-1193,Japan

出　　处：《World Journal of Gastroenterology》2020年第15期1733-1744,共12页世界胃肠病学杂志（英文版）

摘　　要：Third generation of quinolones,such as levofloxacin and moxifloxacin,-containing regimens are often used in second-line or rescue treatment of Helicobacter pylori infection.However,the increasing antibiotic resistance to quinolones affects the efficacies of quinolones-containing therapies in recent years.Therefore,there is a need to enhance the effectiveness of quinolonescontaining therapies.Sitafloxacin,a fourth-generation quinolone,and vonoprazan,a novel potassium-competitive acid blocker,are now available as more effective treatment options.The aim of this paper is to summarize the current evidence of quinolone-containing therapies in rescue treatments,and to discuss the importance of drug sensitivity tests or analysis of gyrA mutation before treatments.

关 键 词：HELICOBACTER pylori LEVOFLOXACIN SITAFLOXACIN MOXIFLOXACIN GYRA Vonoprazan 

分 类 号：R573[医药卫生—消化系统]